SCHEMBL29488164

SCHEMBL29488164

Cc1ccc2c(-c3ccnc(N)n3)c[nH]c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.71
DYRK1A Q13627 6/20 0.71
CDK5 Q00535 6/20 0.71
CDK5R1 Q15078 6/20 0.71
CLK1 P49759 4/20 0.71
CCNB2 O95067 3/20 0.71
CDK1 P06493 3/20 0.71
CCNB1 P14635 3/20 0.71
PRKACA P17612 3/20 0.71
PRKACG P22612 3/20 0.71
PRKACB P22694 3/20 0.71
CCNB3 Q8WWL7 3/20 0.71
CSNK1A1 P48729 2/20 0.71
CSNK1D P48730 2/20 0.71
CSNK1E P49674 2/20 0.71
CSNK1G2 P78368 2/20 0.71
CSNK1G1 Q9HCP0 2/20 0.71
MAP3K14 Q99558 5/20 0.66
NFATC1 O95644 1/20 0.63
MEN1 O00255 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23175317 1.00 GSK3B (0.71) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL28492625 0.83 MAP3K14 (0.80) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL21629009 0.83 GSK3B (0.56) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL29488165 0.83 MAP3K14 (0.80) GSK3BDYRK1ACDK5CDK5R1CLK1
Meridianin D SCHEMBL23539138 0.83 GSK3B (1.00) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL28982786 0.83 GSK3B (1.00) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL30369123 0.83 GSK3B (1.00) GSK3BDYRK1ACDK5CDK5R1CLK1
Meridianin D SCHEMBL31094009 0.83 GSK3B (1.00) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL30554766 0.83 GSK3B (0.56) GSK3BDYRK1ACDK5CDK5R1CLK1
SCHEMBL28982787 0.83 GSK3B (1.00) GSK3BDYRK1ACDK5CDK5R1CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents HANMI PHARM. CO., LTD. (KR) 2025-07-08 US claimed
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS HANMI PHARM. CO., LTD. (KR) 2022-11-10 US claimed
EP-3991733-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS Hanmi Pharm. Co., Ltd. (KR) 2022-05-04 EP claimed
US-20260092051-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME HANMI PHARMACEUTICAL CO LTD (KR) 2026-04-02 US disclosed
US-12433867-B2 Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia HANMI PHARM. CO., LTD. (KR) 2025-10-07 US disclosed
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents HANMI PHARM. CO., LTD. (KR) 2025-07-08 US disclosed
US-12325698-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO., LTD. (KR) 2025-06-10 US disclosed
US-20240423979-A1 THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA HANMI PHARM. CO., LTD. (KR) 2024-12-26 US disclosed
EP-4419106-A1 THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA Hanmi Pharm. Co., Ltd. (KR) 2024-08-28 EP disclosed
CN-118510517-A Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia 韩美药品有限公司 2024-08-16 CN disclosed
CN-115925686-B MERIDIANIN derivatives, lewis acid-promoted coupling synthesis method and application thereof 贵州医科大学 2024-07-30 CN disclosed
WO-2023068858-A1 THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA HANMI PHARM. CO., LTD. (KR) 2023-04-27 WO disclosed
CN-115925686-A Meridianin derivatives, coupling synthesis method and application thereof promoted by Lewis acid 贵州医科大学 2023-04-07 CN disclosed
US-20230002358-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME HANMI PHARM. CO., LTD. (KR) 2023-01-05 US disclosed
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS HANMI PHARM. CO., LTD. (KR) 2022-11-10 US disclosed
EP-3991733-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS Hanmi Pharm. Co., Ltd. (KR) 2022-05-04 EP disclosed
US-20220110913-A1 PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA HANMI PHARM. CO., LTD (KR) 2022-04-14 US disclosed
US-11292786-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same HANMI PHARM. CO., LTD. (KR) 2022-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002358-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME DPYD, TYMS, TYMP GSK3B 3481/4885DYRK1A 4297/4885CDK5 438/4885
US-20220110913-A1 PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA FLT3, MCL1, HGFAC GSK3B 501/4885DYRK1A 586/4885CDK5 1445/4885
US-12325698-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same DPYD, TYMS, TYMP GSK3B 3481/4885DYRK1A 4297/4885CDK5 438/4885
US-20220354842-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS FLT3, MCL1, CSF3R GSK3B 486/4885DYRK1A 1852/4885CDK5 845/4885
US-12350265-B2 Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents FLT3, MCL1, CSF3R GSK3B 486/4885DYRK1A 1852/4885CDK5 845/4885
US-11292786-B2 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same DPYD, TYMS, TYMP GSK3B 3481/4885DYRK1A 4297/4885CDK5 438/4885
US-20240423979-A1 THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA MCL1, FLT3, BCL2 GSK3B 39/4885DYRK1A 185/4885CDK5 1249/4885
US-12433867-B2 Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia FLT3, MCL1, HGFAC GSK3B 501/4885DYRK1A 586/4885CDK5 1445/4885
US-20260092051-A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME FLT3, FLT1, ADK GSK3B 152/4885DYRK1A 360/4885CDK5 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.